Related Experiment Video
Updated: Jan 24, 2026

Intravitreous Injection for Establishing Ocular Diseases Model
Published on: October 1, 2007
ADJUNCTIVE INTRAVITREAL MOXIFLOXACIN AND RANIBIZUMAB IN THE MANAGEMENT OF INTRAOCULAR TUBERCULOMA
Nehali Pant1, Rajiv Raman1, Jyotirmay Biswas2
1Shri Bhagwan Mahavir Vitreoretinal Services, Sankara Nethralaya, Chennai, Tamil Nadu, India ; and.
Purpose:
To evaluate the role of adjunctive intravitreal moxifloxacin and ranibizumab in the management of recalcitrant and treatment-naive cases of intraocular tuberculoma.
Methods:
The study included 10 eyes of nine patients diagnosed with intraocular tuberculoma between June 2022 and March 2025 at a tertiary eye care center in India. All patients received systemic therapy and biweekly intravitreal injections of moxifloxacin (500 µg/0.1 mL) and ranibizumab (0.5 mg/0.05 mL) until clinical and anatomical regression of the tuberculoma. Patients were stratified into two groups: Group A (recalcitrant cases) and Group B (treatment-naive cases). Data on imaging features, number of injections, and visual acuity outcomes were analyzed.
Results:
Group A cases (n = 3) had peripheral or ciliary body granulomas and received a 9-month ethambutol-sparing antitubercular treatment regimen along with local therapy. Two eyes achieved a final visual acuity of 6/6, whereas one developed cataract with secondary angle closure glaucoma. Group B (n = 7) included four macular granulomas and three cases with panuveitis and peripheral lesions. The three macular cases required fewer than three injections, achieving 6/6 visual outcomes. Two cases experienced reactivation and responded well to repeat local and systemic therapy.
Conclusion:
Adjunctive intravitreal moxifloxacin and ranibizumab, when combined with systemic antitubercular treatment and corticosteroids, appears to be a valuable therapeutic option in the management of intraocular tuberculoma, especially in cases with macular involvement. Tailored local therapy based on clinical phenotype may enhance lesion control and reduce systemic treatment duration.
Related Concept Videos
Heart Failure VI: Adjunct Therapies
Tonsillitis II: Management
Impression Management Techniques I: Managing Appearances
Management of Insomnia
Managing Impressions
Cystic Fibrosis: Management
Sinus disease and chronic...

